Cromos Pharma supporting lung cancer clinical trials
November is Lung Cancer Awareness Month. Lung cancer is the most common cause of cancer death worldwide making up almost 25% of all cancer deaths. Every year, more people die of lung cancer than of colon, breast, and prostate cancers combined. In recent years, clinical research has led to significant breakthroughs in the treatment of lung cancer, giving hope to millions of patients worldwide. However, there is still some way to go to reduce deaths from this cancer. Cromos Pharma is proud to play its part in supporting clinical trials to test and develop innovative drugs and interventions for lung cancer.
Lung cancer facts
Smoking is the most common cause of lung cancer. Other risk factors include genetic or familial history, inhalation of second-hand smoke, and radiation treatment for breast or chest cancer. Exposure to toxins such as tar, asbestos, nickel, and chromium in the workplace and exposure to radon can also cause lung cancer.
There are two main type of lung cancer – small cell lung cancer and the most common form – non-small cell lung cancer.
The signs and symptoms of lung cancer are:
- A cough that doesn’t go away or a change in a long-term cough
- Feeling short of breath or wheezing
- Repeated chest infections that won’t go away even after antibiotics
- Coughing up blood-stained phlegm
- Pain in your chest, especially when you cough or breathe in
- Feeling more tired than usual and/or unexplained weight loss
- Hoarse voice, problems swallowing or swelling in the face or neck
As with all cancers, getting tested and diagnosed as early as possible increases your chances of survival.
Cromos Pharma’s oncology track record
Since our establishment in 2004, Cromos Pharma has conducted dozens of oncology clinical studies involving the participation of thousands of patients across our regions including Central and Eastern Europe. These studies have focused on a range of areas from finding innovative targeted therapies, to biosimilar and generic studies, aimed at offering wider access to novel treatments.
A tailored and flexible approach to oncology studies
Cromos Pharma offers a flexible oncology model to international sponsors, focused on optimized study design combined with rapid patient enrollment, to accelerate high quality data results. The Cromos Pharma approach focuses on:
- Optimized study design
- In-depth regulatory expertise across our regions
- Faster start-up timelines
- Rapid patient enrollment
- High quality data
ABOUT CROMOS PHARMA
Cromos Pharma is a US-based, international contract research organization delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic indications. Our expert team, comprised of 95% MDs, has extensive expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.
Cromos Pharma has experience in delivering success in a wide range of trial types, from biosimilars and generics, to successfully managing trials of novel therapeutics in a wide range of clinical indications. Our team provides full-service solutions to international pharma and biotech companies in high-recruiting regions, assuring exceptional data quality. Cromos Pharma combines global expertise with in-depth experience and knowledge in the US, Central and Eastern Europe, Central Asia, Republic of Georgia, and Turkey to offer exceptional patient recruitment. Our team has met or reduced enrollment timelines in 95% of conducted trials.
We provide accelerated study start-up timelines in our regions of operation. Regulatory inspections by FDA and EMA and site audits attest to the highest quality of our clinical data.
Established in 2004, Cromos Pharma has strong regional experience that is supported by a global network of offices. Its international HQ is located in Portland, Oregon, USA and its European HQ is in Dublin, Ireland.
